CEO Harith Rajagopalan (Fractyl)

Af­ter a decade in the type 2 di­a­betes game, Fractyl Lab­o­ra­to­ries recharges with a fresh $100M and a new name

Harith Ra­jagopalan com­pared the way type 2 di­a­betes is man­aged to stick­ing your fin­gers in a dam that’s leak­ing from a num­ber of places.

You can take drugs to low­er your blood sug­ar, cho­les­terol, or blood pres­sure, but you’re not ad­dress­ing what he says is the core is­sue — the meta­bol­ic ab­nor­mal­i­ty that caus­es the dis­ease.

“We’re so busy plug­ging the holes in the dam, we don’t have time to see that the whole in­fra­struc­ture is at risk,” he said. “That in­fra­struc­ture is a full-body sys­temic meta­bol­ic ab­nor­mal­i­ty called meta­bol­ic syn­drome, that we’re ig­nor­ing while we’re so busy try­ing to treat all of the in­di­vid­ual symp­toms of the con­di­tion.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.